Regulation of quantal secretion from developing motoneurons by postsynaptic activity-dependent release of NT-3.
Neurotrophic factors derived from postsynaptic muscle cells may play important roles in the development of presynaptic neuronal functions. In 3-d-old Xenopus nerve-muscle cultures, embryonic spinal neurons that had made natural contact with co-cultured myocytes exhibited spontaneous release of larger packets of acetylcholine (ACh) quanta than those released by the isolated neurons having no contact with any myocyte. Treatment of isolated neurons with neurotrophin-3 (NT-3) for 2 d increased the average sizes of quantal ACh packets at newly formed nerve-muscle synapses, whereas treatment with antibody against NT-3 or with K252a, a specific inhibitor of tyrosine kinase receptors, decreased the quantal size at existing synapses, which suggests that NT-3 supplied by the postsynaptic muscle cell may be responsible for the development and maintenance of the quantal packets. The muscle effect seems to depend on synaptic activities mediated by postsynaptic ACh receptor channels, because chronic treatment of the culture with D-tubocurarine (D-Tc) for 2 d resulted in a marked reduction of the quantal sizes, when assayed after extensive washing of the culture with Ringer's solution. The curare treatment did not affect the postsynaptic ACh receptor sensitivity, because iontophoretically applied ACh induced current responses similar to those of control. Finally, co-treatment of the culture with NT-3 and D-Tc reversed the effect of D-Tc on the quantal size, and this reversal effect was abolished when K252a was also applied concomitantly. Our results suggest that muscle-derived NT-3 participates in the maturation of normal transmitter packets in developing neurons, and the secretion of NT-3 depends on spontaneous synaptic activity.
Liou
J C
JC
Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan 100.
Fu
W M
WM
D000109:Acetylcholine / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology; D002450:Cell Communication; D002478:Cells, Cultured; D004625:Embryo, Nonmammalian; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D026121:Indole Alkaloids; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009046:Motor Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009411:Nerve Endings / Q000187:drug effects / Q000502:physiology; D009414:Nerve Growth Factors / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D009469:Neuromuscular Junction / Q000166:cytology / Q000196:embryology / Q000502:physiology*; D020933:Neurotrophin 3; D018408:Patch-Clamp Techniques; D011950:Receptors, Cholinergic / Q000502:physiology; D013569:Synapses / Q000187:drug effects / Q000502:physiology*; D014403:Tubocurarine / Q000494:pharmacology; D014982:Xenopus laevis
D000906:Antibodies; D002227:Carbazoles; D004791:Enzyme Inhibitors; D026121:Indole Alkaloids; D009414:Nerve Growth Factors; D020933:Neurotrophin 3; D011950:Receptors, Cholinergic; C049985:staurosporine aglycone; D000109:Acetylcholine; D014403:Tubocurarine